RareMed’s Director of Pharmacy Services, Rami El Chammas, and VP Markets and Analytics, Gannon Vanscoy, recently published an article illustrating the importance and necessity of rare-disease HUBs and the value they bring to all network stakeholders including emerging biopharma manufacturers, healthcare providers, and of course, patients. RareMed Solutions is a thought leader in rare disease pharmacy hub services and regularly publishes content describing innovations in advancements in methods to provide better care to rare disease patients.
In this piece, Dr. Chammas and Mr. Vanscoy discuss how launching a life enhancing medicine is a one-time opportunity and the patient service provider (PSP), or pharmacy HUB, can make or break a therapy’s launch success efforts. Selecting a misfit hub can jeopardize program success and result in missed opportunities for patient engagement. The inherent challenges of rare diseases demand a high-touch, personalized approach to program design, implementation, execution, technology, and continuous improvement. RareMed Solutions became an industry pioneer when they launched the first rare-focused HUB in 2018. The launch filled the market gap that existed for providing concierge-level service to smaller, more intensive patient populations.
Dr. Chammas and Mr. Vanscoy go into further detail about how rare-focused HUBs value drivers through right size, right technologies, right experience, right nimbleness, and more. RareMed only takes on programs that will benefit from its specialized expertise. Many other factors play an important role in the success of a Rare-Disease HUB, including pure focus, engaged leaders, constant collaboration, disease state experience, dedicated; specialized teams, custom technology, and rare disease non-commercial pharmacy (NCP).